Evidence map›Paper›PMID 29141174›Full record

ReviewThe New England journal of medicine2017

Diuretic Treatment in Heart Failure.

David H Ellison, G Michael Felker

Erratum issued 3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 164 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03746002 phase4terminatednot on this mapstarted 2019, after this paper: background citation

Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing With Furosemide: a Pilot Study

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2019 to 2020Enrolled3ConditionsFluid Overload, Heart Failure AcuteArmsMetolazone 60 minutes prior to furosemide, Metolazone concurrently with furosemide
NCT03923933 phase2completednot on this mapstarted 2019, after this paper: background citation

Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

TypeinterventionalSponsorHospital General de México Dr. Eduardo LiceagaRan2019 to 2019Enrolled34ConditionsRenal Insufficiency, ChronicArmsChlorthalidone, Bumetanide
NCT07350759 recruitingnot on this mapstarted 2026, after this paper: background citation

An Observational Study to Develop an Algorithm to Predict Decompensation of Congestive Heart Failure (dCHF) Using a Non-Invasive Wearable Device.

Typeobservational_patient_registrySponsorCHFDX,Inc.Ran2026 to 2026Enrolled60ConditionsDecompensated Chronic Heart FailureArmswearable ring device with multiple embedded sensors to detect heart rate, SVO2, respiratory rate, heart rate variability and a number of other related physiologic parameters
3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Review

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

David H EllisonFrom the Oregon Clinical and Translational Research Institute, Oregon Health and Science University and the Veterans Affairs Portland Health Care System, Portland (D.H.E.); and Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC (G.M.F.).
G Michael FelkerFrom the Oregon Clinical and Translational Research Institute, Oregon Health and Science University and the Veterans Affairs Portland Health Care System, Portland (D.H.E.); and Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC (G.M.F.).

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
WNK Kinase Regulation of Thiazide-sensitive NaCl TransportR01DK051496 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI David Hoadley Ellison, CHAO-LING YANG · 1998 to 2026
$8.4M
Role of Kir4.1 in Regulating NCC and ROMK in DCTR01DK054983 · NIDDK · NEW YORK MEDICAL COLLEGE · PI ELLISON, DAVID H, WANG, WENHUI · 2001 to 2020
$7.4M
Role of Kir4.1 in regulating NCC and ROMK in DCTR01DK133220 · NIDDK · NEW YORK MEDICAL COLLEGE · PI ELLISON, DAVID HOADLEY, WANG, WENHUI · 2022 to 2025
$2.6M
Renal Effects of AldosteroneI01BX002228 · VA · PORTLAND VA MEDICAL CENTER · PI ELLISON, DAVID H · 2014 to 2021
–
BLRD VA I01 BX002228NCATS NIH HHS UL1 TR002369NIDDK NIH HHS R01 DK051496NIDDK NIH HHS R01 DK054983NIDDK NIH HHS R01 DK133220
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acute DiseaseHeart FailureHumansKidneySodium Potassium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter Inhibitors

Identifiers

PMID29141174
PMCPMC5811193

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.